REGENXBIO Inc. — 2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017. The filing also reports unaudited fourth-quarter results. REGENXBIO is a clinical-stage gene therapy company with no approved products or product-sales revenue; its business centers on developing therapies and licensing its NAV AAV-vector platform.
Financial performance and position
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $10.393 million | $4.589 million |
| Operating expenses | $86.278 million | $69.929 million |
| Operating loss | $(75.885) million | $(65.340) million |
| Net loss | $(73.169) million | $(62.967) million |
| Net loss per share | $(2.45) | $(2.38) |
| Cash used in operating activities | $(57.992) million | $(48.558) million |
- Revenue rose about 127%, primarily from commercial license fees and $1.85 million of license milestones. License revenue was $10.385 million; grant revenue was $0.008 million and reagent sales were nil.
- Research and development expense increased 26% to $57.224 million; general and administrative expense increased 15% to $27.229 million. The company attributed spending growth principally to staffing, clinical materials and manufacturing/process development, facilities, and depreciation.
- Fourth-quarter 2017 revenue was $2.040 million, operating expenses $18.638 million, and net loss $(15.997) million, compared with fourth-quarter 2016 revenue of $1.696 million and net loss of $(19.608) million.
- At year-end, cash and cash equivalents were $46.656 million and marketable securities $129.738 million, totaling approximately $176.4 million. Working capital was $153.560 million; total assets were $198.677 million and liabilities $15.648 million.
- No borrowings or interest expense were reported for 2017. The filing does not present a meaningful product gross margin: the company had no product sales and remained loss-making.
- Investing cash flow was $(4.790) million, including $7.160 million of property and equipment purchases. Financing cash flow was $84.598 million, primarily from a follow-on share offering. The company reported no off-balance-sheet arrangements.
Material changes and notable items
- Loss widened by $10.202 million versus 2016 as operating expenses grew faster than revenue. Operating cash use increased by $9.434 million.
- Revenue was highly concentrated: AveXis accounted for approximately 68% of 2017 revenue. License revenue is contingent and may vary substantially between periods.
- The March/April 2017 follow-on offering generated approximately $81.5 million in net proceeds. Common shares outstanding at December 31, 2017 were 31.295 million; 31.655 million were outstanding as of March 2, 2018.
- After year-end, in January 2018, AveXis paid $80 million for expanded SMA licensing rights. Further contractual payments include $30 million on each of the first two anniversaries and potential commercial milestones of up to $120 million. These amounts were not FY 2017 revenue. The filing stated that year-end liquidity was expected to fund operations for at least 12 months from the report date; it does not give a clear post-payment cash balance.
- Marketable securities were exposed to interest-rate risk: a hypothetical immediate 100-basis-point increase was estimated to reduce their fair value by $0.7 million.
Pipeline, outlook, risks and contingencies
- RGX-314 (wet AMD): Phase I enrolled and dosed 18 patients across three cohorts. Management reported generally good tolerability in the first 12 patients and dose-dependent protein expression in the first two cohorts; topline data were expected in late 2018.
- RGX-501 (HoFH): Phase I/II had dosed five patients. One first-cohort patient experienced a drug-related serious adverse event of hypotension associated with a mild inflammatory response; it resolved within hours. Management expected topline data in late 2018.
- RGX-111 and RGX-121 (MPS I and MPS II): INDs were active. Management expected to begin trials in mid-2018 and provide interim updates in late 2018. Both had FDA orphan-drug and rare-pediatric-disease designations.
- Management also expected to announce another lead candidate in the second half of 2018. These are development expectations, not financial guidance; timing and outcomes are uncertain.
- Key risks include early-stage clinical uncertainty, potential immune or other safety effects, regulatory and manufacturing hurdles, patient recruitment, dependence on partners and contract manufacturers, and the need for future financing. Management expected continued losses and increasing research, development and administrative spending.
- A third party opposed a Penn-owned European AAV8 patent in June 2017; the matter was at an early stage and the outcome was not estimable. The company said it intended to assist Penn in defending the patent. Management reported no pending legal action expected to materially affect the company.
- Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2017. The independent auditor issued an unqualified opinion on the financial statements; no auditor attestation on internal control was included because the company was an emerging growth company.
- The company expected adoption of the new revenue-recognition standard in 2018 to materially affect license-revenue timing and disclosures, including acceleration of certain annual maintenance-fee revenue. The quantitative effect had not been finalized.
Important facts for investors to verify
- Follow subsequent clinical disclosures for RGX-314 and RGX-501, including durability, efficacy, immune findings and any additional serious adverse events.
- Confirm actual initiation and progress of RGX-111 and RGX-121 trials, and whether management’s stated 2018 milestones were achieved.
- Review the AveXis amendment’s cash receipts, remaining scheduled payments, milestones, royalties and any change-of-control provisions; distinguish post-year-end cash from December 31, 2017 liquidity.
- Assess reliance on AveXis and other licensees, the timing and variability of milestone or royalty income, and the consequences if partner programs stall.
- Monitor operating cash burn, clinical/manufacturing spending, financing needs and dilution; year-end cash-runway statements were based on the then-current business plan.
- Track the European AAV8 patent opposition and the effect of 2018 revenue-recognition adoption on reported licensing revenue.